Jasper Therapeutics, Inc. (JSPR) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-02-10

Jasper Therapeutics, Inc. (JSPR) — no SEC Form 4 insider filings recorded in the last 90 days. 4 Form 8-K material event filings were reported by JSPR in the last 90 days. InsiderAlpha tracks every JSPR SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About Jasper Therapeutics, Inc. (JSPR)

SEC CIK	0001788028

90-Day SEC Filing Activity

Form 8-K filings (90d)	4
Latest Form 4 filing	2026-02-10

Recent JSPR Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2025-09-22	MARTELL RON	President and CEO	P — Open-market purchase	41.0K	$2.43	$100K	SEC
2025-09-22	WIGGANS THOMAS G	Director	P — Open-market purchase	41.0K	$2.43	$100K	SEC
2025-09-22	Lucas Svetlana	Director	P — Open-market purchase	20.0K	$2.43	$49K	SEC
2025-09-22	Shizuru Judith Anne	Director	P — Open-market purchase	41.0K	$2.43	$100K	SEC
2024-12-12	Mahal Jeetinder Singh	Chief Operating Officer	M — Option exercise [10b5-1]	900	$7.10	$6K	SEC
2024-12-12	Mahal Jeetinder Singh	Chief Operating Officer	S — Open-market sale [10b5-1]	900	$22.11	$20K	SEC

All transactions sourced from SEC EDGAR Form 4 filings for Jasper Therapeutics, Inc. (JSPR). Updated in real time as new filings are submitted to the SEC.

Recent JSPR Form 8-K Material Events

2026-06-09 — Item 3.01 [SEC]
2026-06-01 — Item 7.01, 9.01 [SEC]
2026-05-21 — Item 5.02, 9.01 [SEC]
2026-05-14 — Item 2.02, 9.01 [SEC]
2026-03-30 — Item 2.02, 9.01 · Earnings · neutral [SEC]
Jasper Therapeutics reported financial results for Q4 2025 and full year 2025, along with a corporate update. The filing provides standard quarterly and annual financial reporting without explicit beat/miss or guidance language.

Recent Insider Filings

2026-02-10 — Mahal Jeetinder Singh (CEO and President)
2026-01-06 — MARTELL RON (President, CEO and Director)
2026-01-06 — Mahal Jeetinder Singh (Chief Operating Officer)
2026-01-06 — CROSS HERB (Chief Financial Officer)
2025-09-22 — Shizuru Judith Anne (Director)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in JSPR insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

JSPR Insider Trading — FAQ

What is the latest insider trade for JSPR?: Jasper Therapeutics, Inc. (JSPR) had 0 insider filings in the last 90 days, with the most recent on 2026-02-10. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying JSPR stock?: 0 insider purchases of JSPR were filed in the last 90 days.
How many insiders are selling JSPR stock?: 0 insider sales of JSPR were filed in the last 90 days.
Where can I see JSPR SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every JSPR SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Learn More

Open the live JSPR dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.